Why I’d invest £1,000 in the Glaxo share price today

Harvey Jones says GlaxoSmithKline plc (LSE: GSK) remains a FTSE 100 (INDEXFTSE: UKX) dividend income hero.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100-listed pharmaceutical giant GlaxoSmithKline (LSE: GSK) has long been the go-to stock for investors wanting a stable, long-term income stream. But there’s no question about it, enthusiasm has abated in recent years.

Frozen income

The dividend is still there but it’s been frozen at 80p for the last five years, as management looked to pour its money into R&D to get its once-mighty drugs pipeline flowing again. There’s no respite this year, with City analysts expecting the payout to fall slightly to 79.97p, both in 2019 and 2020.

Yet that’s no reason to shun this £77bn giant, which still offers a healthy forecast yield of 5.2%, beating the FTSE 100 average of 4.4%. Cover is a relatively healthy 1.4. The group’s return on capital employed is also a dizzying 64%.

Glaxo’s stock is even available at a tiny discount, currently trading at 14 times future earnings. Yet it doesn’t completely convince, with earnings forecast to fall 8% this year, although it’s slated to return to growth in 2020. Analysts are expecting the firm to report a net profit of £5.6bn for 2019, which would be a six-year high. 

Buy and hold

That’s the short-term stuff. In the longer run, I believe a good portfolio is made up of stocks like these, or should at least have exposure to them.

Healthcare is a terrific long-term theme as the global population ages – the sector was the best performer on the S&P 500 in 2018. Glaxo’s revenue and profits both look set to grow strongly in 2020 and, fingers crossed, it will be lift-off after that. Now may be a good time to get stuck in while it’s still relatively cheap.

Comeback kid?

Now here’s a very different pharma. Investors in inhaled drug device development specialist Vectura Group (LSE: VEC) have seen the stock lose more than half its value in the last couple of years.

Today, the £466m firm issued its 2018 preliminary results, but the market is underwhelmed. The stock is down 2.5% at time of writing, despite a 8.4% rise in full-year reported revenue to £160.5m, while inhaled portfolio revenues jumped 15% to £131.1m.

Cashing out

R&D costs of £55.5m were at the lower end of guidance as it refocuses its portfolio prioritisation and boosts R&D productivity. Adjusted EBITDA rose 51.2% to £39m, “driven by revenue growth, improved gross margin, lower R&D costs and productivity improvements.” However, it posted an operating loss of £105.4m, after ongoing amortisation and exceptional items, as it continues to take a hit from its disappointing phase III study of VR475 asthma drug-device combination.

Vectura did generate strong cash generation from operations, up 30.5% to £35.1m. This left it with closing cash and cash equivalents of £108.2m, while it also completed a £13.8m share buyback.

The pharma and biotech group is tilting at an airways diseases market that’s worth $40bn globally, but hasn’t fully recovered from a series of disappointing trading updates. Its share price slump has left it trading at 15.5 times earnings, which may tempt some. Earnings fell 53% in 2017, but are up 8.4% today, with 4% growth anticipated for 2019, and then 22% in 2020. The future looks brighter, but I’m still struggling to recommend it.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

3 value shares for investors to consider buying in 2025

Some value shares blew the roof off during 2024, so here are three promising candidates for investors to consider next…

Read more »

Investing Articles

Can this takeover news give Aviva shares the boost we’ve been waiting for?

Aviva shares barely move as news of the agreed takeover of Direct Line emerges. Shareholders might not see it as…

Read more »

Investing Articles

2 cheap FTSE 250 growth shares to consider in 2025!

These FTSE 250 shares have excellent long-term investment potential, says Royston Wild. Here's why he thinks they might also be…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Has the 2024 Scottish Mortgage share price rise gone under the radar?

The Scottish Mortgage share price rise has meant a good year for the trust so far, but not as good…

Read more »

Investing Articles

Will the easyJet share price hit £10 in 2025?

easyJet has been trading well with rising earnings, which reflects in the elevated share price, but there may be more…

Read more »

Investing Articles

2 FTSE shares I won’t touch with a bargepole in 2025

The FTSE 100 and the FTSE 250 have some quality stocks. But there are others that Stephen Wright thinks he…

Read more »

Dividend Shares

How investing £15 a day could yield £3.4k in annual passive income

Jon Smith flags up how by accumulating regular modest amounts and investing in dividend shares, an investor can build passive…

Read more »

Investing Articles

Could this be the FTSE 100’s best bargain for 2025?

The FTSE 100 is full of cheap stocks but there’s one in particular that our writer believes has the potential…

Read more »